IDEAYA licenses darovasertib ex-US to Servier for $210M upfront plus milestones up to $320M

IDEAYA Biosciences, Inc.

Exclusive license to Servier for darovasertib outside the US; all human diagnostic, prophylactic, therapeutic uses.
Upfront $210M; up to $100M development/regulatory milestones and $220M commercial milestones.
Royalties on ex-US net sales: mid-teens to low-twenties percent.
Cash runway extended by at least 12 months; expects funding into 2030 under current plan.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.